Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Acta Oncologica

Volumn 49, Issue 4, 2010, Pages 506-508

  Stagno, Fabio ^a   Vigneri, Paolo ^b   Fabro, Vittorio Del ^a   Stella, Stefania ^b   Cupri, Alessandra ^a   Massimino, Michele ^b   Consoli, Carla ^a   Tambè, Loredana ^a   Consoli, Maria Letizia ^b   Antolino, Agostino ^c   Di Raimondo, Francesco ^a  

^a Ospedale Ferrarotto   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c AO Maria Patern Arezzo ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CHROMOSOME TRANSLOCATION; CHROMOSOME VARIANT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; GENOMIC INSTABILITY; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; GENOMIC INSTABILITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RISK FACTORS; THIAZOLES; TRANSLOCATION, GENETIC;

EID: 77951225879     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841861003660031     Document Type: Article

References (9)

1. Heim S, Billström R, Kristoffersson U, Mandahl N, Strömbeck B, Mitelman F. Variant Ph translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 1985;18: 215-227
2. Richebourg S, Eclache V, Perot C, Portnoi MF, Van den Akker J, Terré C, et al. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet 2008;182:95-102.
3. Penserga ET, Skorski T. Fusion tyrosine kinases: A result and cause of genomic instability. Oncogene 2007;26:11-20.
4. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820
5. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
6. Mitelman F. ISCN: An international system for human cytogenetic nomenclature. Basel: S. Karger; 1995.
7. Marin D, Khorashad JS, Foroni L, Milojkovic D, Szydlo R, Reid AG, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009;145:373-375
8. Gorusu M, Benn P, Li Z, Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 2007;173:97-106.
9. El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S,Giles F, Garcia-Manero G, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004; 125:187-195